A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with <i>Candida</i> skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
Distribution of the number of citations over years.